Skip to content

Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population

Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From an Asymptomatic Population

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04561102
Enrollment
644
Registered
2020-09-23
Start date
2020-09-11
Completion date
2021-02-28
Last updated
2022-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2

Brief summary

This is a prospective, single-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one nasal swab will be tested with an EUA approved COVID test. The other nasal swab sample will be stored and a subset (approximately 250 specimens) will be tested with the COVIDSeq Test. Results of all testing will be provided to the sponsor for statistical analysis. Results from the comparator EUA test will be provided to the collection site investigator or designated collection site study staff. No medical treatment, guidance on treatment decisions, nor medical care will be provided.

Interventions

DIAGNOSTIC_TESTDiagnostic test for detection of SARS-CoV-2

The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19

Sponsors

Helix OpCo, LLC
CollaboratorUNKNOWN
Illumina, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Subject Inclusion Criteria: An individual must meet the criteria below to be eligible. * Individual is attending or invited to visit a participating collection site. * Individual is 18 years or older at the time of consent. * Individual is feeling well at the time of consent or specimen collection and does not have any of the following symptoms of COVID-19 per the current CDC guidance such as cough, shortness of breath or difficulty breathing, fatigue, fever or chills, muscle or body aches, headache, sore throat, new loss of taste or smell, congestion or runny nose, nausea or vomiting, or diarrhea. * Individual is willing to participate in study procedures and able to provide written informed consent in the English language. Subject

Exclusion criteria

An individual cannot meet the below criteria. * Individual is confirmed to have COVID-19 and continues to require isolation in accordance with current CDC guidelines at the time of consent or specimen collection. * Individual is asymptomatic but suspected to have COVID-19 due to recent close contact (as currently defined by the CDC) with a person with COVID-19 and continues to require quarantine in accordance with current CDC guidelines at the time of consent or specimen collection. \[5\] * Individual had symptoms of COVID-19 less than 10 days before time of consent or specimen collection.

Design outcomes

Primary

MeasureTime frame
Positive percent agreement (PPA) and negative percent agreement (NPA) between the COVIDSeq Test and a comparator EUA test for the detection of SARS-CoV-2 RNA1 month

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026